6:36 PM
 | 
Feb 28, 2008
 |  BC Extra  |  Company News

Merck, AstraZeneca shuffle JV

Merck (NYSE:MRK) will receive a net payment of about $2.6 billion this quarter from AstraZeneca (LSE:AZN; NYSE:AZN) under a restructuring of the companies' Astra Merck JV, which markets AstraZeneca's drugs in the U.S. Merck will receive about $4.3 billion for relinquishing rights to four of the JV's drugs: Toprol-XL metoprolol to treat hypertension, angina and...

Read the full 277 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >